Collectively, our studies illustrate the dynamic nature of NRP2 isoform expression in breast cancer and suggest that targeting NPR2 isoform-specific signaling pathways or NRP2-isoform expressing TAM subsets may be leveraged for macrophage reprograming or TAM-targeted immunotherapies. Here, NPR2 is linked to breast cancer.